The impact of the US priority review voucher on private-sector investment in global health research and development. - National Genomics Data Center (CNCB-NGDC)

Advanced Search

The impact of the US priority review voucher on private-sector investment in global health research and development.

Andrew S Robertson, Rianna Stefanakis, Don Joseph, Melinda Moree

Author Information

Andrew S Robertson: BIO Ventures for Global Health, San Francisco, California, United States of America.

PMID: 22953004 DOI: 10.1371/journal.pntd.0001750

No abstract text available.

Lancet. 2009 Apr 25;373(9673):1414 [PMID: 19399998]
Lancet. 2002 Jun 22;359(9324):2188-94 [PMID: 12090998]
PLoS One. 2010 May 12;5(5):e10610 [PMID: 20485552]
N Engl J Med. 2008 Nov 6;359(19):1981-3 [PMID: 18987367]
Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24 [PMID: 16522573]
Bull World Health Organ. 2005 Apr;83(4):301-7 [PMID: 15868022]
PLoS Med. 2009 Feb 3;6(2):e30 [PMID: 19192946]

Biomedical Research

Communicable Diseases

Global Health

Health Policy

Humans

Infection Control

Investments

Neglected Diseases

Private Sector

Research

United States

Journal Article Review

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.Can India lead the way in neglected diseases innovation?The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review.Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases.Open drug discovery for the Zika virus.Research for new drugs for elimination of onchocerciasis in Africa.